Clinical Trial Update: RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Rituximab versus Fumarate in newly diagnosed relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Fumarate (dimethyl fumarate)
• Rituximab (rituximab)

Snippet

Sponsor: Anders Svenningsson | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED